Data show that bortezomib enhances NFκB activity in CD8+ T cells, in contrast to multiple myeloma cells where bortezomib was shown to inhibit NFκB activity by preventing proteosomal degradation of IκBα [61]. Here, NFKB1 is linked to plasma cell myeloma.